Welcome to chemicalbook!
400-158-6606
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

ChemicalBook > Product Catalogue >Biochemical Engineering >Inhibitors >Transmembrane Transporters >Calcium Channel Inhibitors >Ranolazine

Ranolazine

Ranolazine Structure
  • ₹0
  • Product name: Ranolazine
  • CAS: 95635-55-5
  • MF: C24H33N3O4
  • MW: 427.54
  • EINECS:620-450-7
  • MDL Number:MFCD00864690
  • Synonyms:1- 3-(2-Methoxyphenoxy)-2-hydroxypropyl -4- ...;1-Piperazineacetamide,N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-;N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]ethanamide;N-(2,6-diMethylphenyl)-2-{4-[(2R)-2-hydroxy-3-(2-Methoxyphenoxy)propyl]piperazin-1-yl}acetaMide;Ranolazine(Ranexa);100MG/500MG/1KG;Ranolazine N-(2,6-Dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide;Ranolazine (100 mg)
Manufacturer Product number Product description Packaging Price Updated Buy

Properties

Melting point :119-1200C
Boiling point :624.1±55.0 °C(Predicted)
Density :1.174±0.06 g/cm3(Predicted)
storage temp. :Sealed in dry,Room Temperature
solubility :DMSO (Slightly), Methanol (Slightly)
form :Solid
pka :14.06±0.20(Predicted)
color :White
CAS DataBase Reference :95635-55-5(CAS DataBase Reference)

Safety Information

Symbol(GHS): GHS hazard pictograms
Signal word: Warning
Hazard statements:
Code Hazard statements Hazard class Category Signal word Pictogram P-Codes
H302 Harmful if swallowed Acute toxicity,oral Category 4 Warning GHS hazard pictograms P264, P270, P301+P312, P330, P501
Precautionary statements:
P264 Wash hands thoroughly after handling.
P264 Wash skin thouroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P301+P312 IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P330 Rinse mouth.
P501 Dispose of contents/container to..…

Description

Ranolazine is an orally available, extended release drug for the treatment of chronic angina in patients who have failed to respond to prior angina therapy. Chronic stable angina (CSA) is a common symptom of coronary artery disease wherein plaques in the coronary vasculature restrict blood flow to the heart, which in turn leads to insufficient oxygenation of the heart, typically during physical exertion or emotional stress. A vast majority of the existing anti-anginal and anti-ischemic therapies aim to correct the imbalance between myocardial oxygen demand and supply through mechanisms that produce reductions in heart rate or blood pressure.

Related product price